GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
P

PYC Therapeutics PYC.AX · AUD

Health Care · ASX · 🇦🇺 Australia

Compare

1.99

+5.85%

Close of 9 Nov 2026, in AUD

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

About PYC Therapeutics

Its shares trade on ASX under the ticker PYC.AX. It has been listed since 30 March 2005. In the fiscal year to 30 June 2025, it reported revenue of A$23.5m and a net loss of A$50.3m. At that date it held total assets of A$183.3m and shareholders' equity of A$169.6m.

PYC Therapeutics Ltd. engages in the discovery, research, and development of novel therapeutics. The company is headquartered in Nedlands, Western Australia. The company went IPO on 2005-03-30. The firm is engaged combining its cell-penetrating peptides (CPP) technology with in ASOs to create a pipeline of drugs called CPP-ASOs. The firm intends to expand its pipeline to include other disease indications and therapeutic areas such as genetic neurodegenerative and liver diseases. Its pipeline products is Ocular, which is focused on treating retinitis pigmentosa and inherited retinal disease.

Figures and description from our data supplier, not checked against the company's own report.

Company facts

Sector
Health Care
Industry
Biotechnology
Listed since
30 Mar 2005
Employees
23
Website
pyctx.com ↗

Leadership

Pay as last reported

  • Mr. Alan TribeNon-Executive Chairman of the BoardA$70,000
  • Dr. Rohan HockingsChief Executive Officer, Executive Director, since 2016A$417,503
  • Mr. Andrew TaylorChief Financial Officer, Joint Company Secretary
  • Dr. Glenn NoronhaChief Development Officer
  • Mr. Kevin HartJoint Company Secretary
  • Mr. Jason HaddockNon-Executive Independent DirectorA$109,334
  • Dr. Michael RosenblattNon-Executive Independent DirectorA$111,291

Environmental, social and governance

Scores out of 100, from our data supplier

ESG
Overall
0
Environment
0
Social
0
Governance
0

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.